November 8, 2012

aTyr Pharma to Present Data for Inflammatory Myopathy and Interstitial Lung Disease at the 2012 American College of Rheumatology Annual Meeting
Detailed Characterization of Orphan Autoimmune Disease Provides Insight into Jo-1 Antibody Response
Read More»

June 18, 2012

aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
Dr. John Mendlein to Speak at Upcoming BIO International Convention
Read More»

December 14, 2011

aTyr Pharma Appoints Dr. Alan Ezekowitz to Therapeutic Advisory Board
Pioneer in Innate Immunity and Industry Expert to Help Guide the Discovery and Development of Physiocrine-based Medicines
Read More»

August 30, 2011

aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology
Dr. Jeffrey Greve Named Vice President, Research; Dr. Andrew Cubitt Named Vice President, Intellectual Property
Read More»

June 17, 2011

aTyr Pharma Honored with Red Herring 100 North America Award for Discovering and Developing Innovative Medicines Based on Physiocrine Biology
Read More»

aTyr Pharma

The Physiocrine Therapeutics Company

At aTyr, our mission is to improve patient care with innovative biologic drugs based on the unique biology of Physiocrines™.  Physiocrines are natural, endogenous human proteins that function as extracellular signals, and have therapeutic applications varying from hematology, inflammation, metabolic disorders, muscle disease, neurology and vascular disorders.  Overlooked by previous genomics or secretome discovery efforts, Physiocrines are an untapped source of novel protein therapeutics. 

PHYSIO - physical or physiological, Greek “physis”,  meaning origin, natural order

+

     - CRINE: distinct, separate; Greek “krinein” meaning to distinguish